Have any questions? 706-721-6582 or cts@augusta.edu
The purpose of this study is to see whether the addition of ixazomib to ibrutinib chemotherapy is effective in treating people who have relapsed or refractory mantle cell lymphoma and to examine the side effects assicated with ixazomib in combination with ibrutinib.